Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632227 | 1.00 | TRPA1 (0.55) | TRPA1LMNAMAPK1TAAR1CYP2D6 | |
| SCHEMBL5475206 | 1.00 | TRPA1 (0.55) | TRPA1LMNAMAPK1TAAR1CYP2D6 | |
| SCHEMBL11829363 | 0.86 | USP5 (0.44) | TRPA1LMNAMAPK1CYP2D6FFAR1 | |
| SCHEMBL3267184 | 0.82 | RIPK1 (0.48) | TRPA1LMNAMAPK1TAAR1CYP2D6 | |
| SCHEMBL23894335 | 0.82 | TRPA1 (0.57) | TRPA1LMNAMAPK1TAAR1CYP2D6 | |
| SCHEMBL28315848 | 0.82 | TRPA1 (0.57) | TRPA1LMNAMAPK1TAAR1CYP2D6 | |
| SCHEMBL11823475 | 0.80 | ALDH1A1 (0.48) | TRPA1LMNAMAPK1CYP2D6 | |
| SCHEMBL11827232 | 0.80 | ALDH1A1 (0.43) | TRPA1LMNAMAPK1FFAR1 | |
| SCHEMBL27564208 | 0.79 | LMNA (0.52) | LMNAMAPK1CYP2D6SRCAOC3 | |
| SCHEMBL27564209 | 0.79 | LMNA (0.52) | LMNAMAPK1CYP2D6SRCAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TRPA1 3576/4885LMNA 1707/4885MAPK1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.